SLC5A2 and heart failure: The substantial rise in the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors (with 61.90% use for STEMI with new LBBB, p < 0.001, and 38.09% use for STEMI without LBBB, p = 0.028) in both groups indicates their growing importance in heart failure therapy, underscoring their benefits in reducing hospitalization rates and improving cardiovascular health.